Benzinga | Aug 6, 2020 04:43PM EDT

ZIOPHARM Oncology Q2 EPS $(0.09), Inline

ZIOPHARM Oncology (NASDAQ:ZIOP) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is unchanged from the same period last year.